8 Questions on Diabetes Drugs for Cardioprotection

News
Slideshow

Slideshow

Cardioprotective effects of sodium–glucose cotransporter 2 inhibitors (SGLT2is) and glucagon-like peptide 1 receptor agonists (GLP-1 RAs) in patients with type 2 diabetes (T2D) and atherosclerotic cardiovascular disease (ASCVD) have been reported in a number of high-profile, landmark clinical trials.

Take this quick quiz to test your knowledge of key findings.

Recent Videos
New Research Amplifies Impact of Social Determinants of Health on Cardiometabolic Measures Over Time
© 2025 MJH Life Sciences

All rights reserved.